NRx Pharmaceuticals to File NRX-100 NDA by June 2026 for Suicidal Depression
NRx Pharmaceuticals received FDA confirmation that existing adequate and well-controlled trials plus real world evidence from Osmind, Inc. can support an NDA for NRX-100 without additional clinical studies. The company plans to submit its NDA by June 2026 for a broadened depression indication including patients with suicidal ideation.
1. FDA Meeting Confirms NDA Path for NRX-100
NRx secured confirmatory minutes from an in-person Type C meeting with leaders of the FDA Division of Psychiatry Products, Office of Neuroscience, and Center for Drug Evaluation, affirming a clear pathway to New Drug Application for NRX-100 based on existing data.
2. Acceptance of Real World Evidence and No New Trials
The FDA agreed to review substantial evidence of efficacy drawn from existing adequate and well controlled clinical trials alongside real world evidence from Osmind, Inc., and confirmed that no additional clinical or nonclinical studies or bridging trials are required.
3. Broadened Indication and Submission Plans
NRx will pursue a primary indication for treating depression in patients with severe suicidal ideation rather than a narrower subset, and intends to file its New Drug Application by June 2026.
4. Pending ANDA for Preservative-Free Ketamine
In parallel, NRx has an Abbreviated New Drug Application under review for preservative-free ketamine in anesthesia, with an FDA decision expected in Summer 2026.